NIOX Group

Update in progress

NIOX.L (LSE)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

NIOX Group Plc designs, develops, and commercializes medical devices for diagnosing, monitoring, and managing asthma and COPD worldwide. Its NIOX VERO system is a portable, non-invasive point-of-care device that measures fractional exhaled nitric oxide (FeNO) using a compact monitor, disposable mouthpieces, and breathing handles. Formerly Circassia Group Plc, it was renamed NIOX Group in 2022, was incorporated in 2006, and is based in Oxford, UK.

Company score

Sentiment: -0.21; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: -0.02; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: -0.11; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive